Focused On-demand Library for Cell cycle checkpoint protein RAD1

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
O60671

UPID:
RAD1_HUMAN

ALTERNATIVE NAMES:
DNA repair exonuclease rad1 homolog; Rad1-like DNA damage checkpoint protein

ALTERNATIVE UPACC:
O60671; O75572; O95304; Q1W161; Q5KSM0; Q5KSM1; Q9UEP1

BACKGROUND:
The Cell cycle checkpoint protein RAD1, with alternative names DNA repair exonuclease rad1 homolog and Rad1-like DNA damage checkpoint protein, is integral to the 9-1-1 complex involved in DNA repair. It enhances the efficiency of DNA polymerase beta, endonuclease FEN1, and DNA ligase I in long-patch base excision repair processes. Additionally, it is crucial for the recruitment of RHNO1 to sites of double-stranded breaks during the S phase, highlighting its significant role in maintaining genomic stability.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Cell cycle checkpoint protein RAD1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.